YOLFTbeta
CNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc

CNSP · NASDAQ · Healthcare / Biotechnology

2.89USD-0.73 (-20.17%)

Price History

Full chart

Market Stats

Previous Close3.62
Open3.70
Day Range2.89 – 3.70
52-Week Range1.90 – 10.59
Volume17.45K
Market Cap7.21M
P/E (TTM)0.00
Forward P/E0.00
EPS-15.39
Dividend Yield0.00%
Beta1.00
50-Day Avg5.48
200-Day Avg4.75

About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Rami Levin M.B.A.
  • Employees8
  • Headquarters2100 West Loop South, Houston, TX, United States, 77027, USA
  • Websitehttps://cnspharma.com

Leadership

  • Mr. Rami Levin M.B.A.President, CEO & Director · b. 1969
  • Mr. Steve O'Loughlin M.B.A.Chief Financial Officer · b. 1985
  • Mr. Eric Faulkner M.B.A., M.Sc.Chief Technology Officer · b. 1973
  • Mr. Dylan Wenke M.B.A.Chief Business Officer
  • Dr. E. Lynne Kelley F.A.C.S., M.D.Chief Medical Officer · b. 1963

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00000000
Cost of Revenue--1.96K11.10K13.07K11.76K4.13K3.31K-
Gross Profit---1.96K-11.10K-13.07K-11.76K-4.13K-3.31K-
Operating Expense--3.83M9.44M14.47M14.92M18.86M14.90M-
Operating Income-516.25K-881.79K-3.83M-9.45M-14.49M-14.93M-18.87M-14.90M-15.99M
EBITDA--6.46M-3.83M-9.44M-14.47M-15.26M-18.83M-14.84M-15.83M
Net Income-526.47K-7.39M-3.92M-9.46M-14.50M-15.27M-18.85M-14.86M-15.85M
R&D32.64K21.27K1.85M5.06M9.81M9.30M14.10M9.29M9.77M
Interest Expense4.26K46.70K44.23K3.26K9.29K7.03K13.80K16.12K15.23K

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets162.19K683.33K7.91M15.85M8.76M13.05M1.70M8.70M8.62M
Total Liabilities220.73K1.23M311.00K1.91M2.14M4.92M6.13M2.52M4.10M
Total Equity-58.53K-549.30K7.60M13.95M6.62M8.13M-4.43M6.18M4.52M
Cash110.54K282.74K7.24M14.04M5.00M10.06M548.72K6.46M7.20M
Total Debt121.83K316.92K-439.29K387.79K409.97K300.81K326.07K328.57K
Net Debt11.28K34.18K-7.24M-13.60M-4.62M-9.65M-247.91K-6.14M-6.87M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-112.20K-716.38K-3.55M-7.32M-13.54M-10.56M-14.14M-17.11M-13.81M
Investing Cash Flow-20.12K-20.12K-20.12K-17.95K-5.75K-4.42K-3.90K-4.19K-18.18K
Financing Cash Flow222.74K1.16M10.26M14.13M4.51M15.61M4.64M23.03M14.57M
Capital Expenditure3520.12K17.95K5.75K4.42K3.90K4.19K18.18K
Free Cash Flow-112.20K-716.38K-3.57M-7.34M-13.54M-10.56M-14.14M-17.12M-13.83M
FCF to OCF100.00%100.00%100.57%100.25%100.04%100.04%100.03%100.02%100.13%

Earnings

Report DateJun 28, 2019Aug 28, 2019Dec 20, 2019Mar 12, 2020May 15, 2020Aug 10, 2020Nov 12, 2020Feb 12, 2021May 13, 2021Aug 13, 2021Nov 12, 2021Mar 3, 2022May 13, 2022Aug 12, 2022Nov 10, 2022Mar 31, 2023May 15, 2023Aug 14, 2023Nov 14, 2023Mar 14, 2024May 15, 2024Aug 14, 2024Nov 14, 2024Mar 31, 2025May 15, 2025Aug 14, 2025Nov 14, 2025Mar 31, 2026Aug 12, 2026Nov 13, 2026
EPS Estimate0.000.00-27000.04-0.90-90000.13-72000.10-112500.16-105750.15-108000.15-117000.16-132000.18-4.80-126000.18-72000.10-90000.13-2.40--84600.03-51900.02----60.00-7.33-2.00-9.60-6.63-5.09-0.24-
EPS Actual-0.47-0.03-45000.06-5.10-108000.15-135000.19-108000.15-162000.23-135000.19-135000.19-126000.18-3.00-63000.09-81000.11-81000.11-3.82-2.59-31200.01-32400.01-28622.96-0.41-6.72-150.00-37.33-1.58-6.42-5.76-10.15-0.38-
Surprise---66.67%-466.67%-20.00%-87.50%4.00%-53.19%-25.00%-15.38%4.55%37.50%50.00%-12.50%10.00%-59.21%-63.12%37.57%----150.00%-409.28%21.00%33.13%13.12%-99.41%-58.33%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-

Key Statistics & Ratios

Market Cap7.21M
Enterprise Value4.81M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.41
EPS-15.39
Book Value12.45
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-16.90M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-106.62%
Return on Assets-58.01%
Shares Outstanding1.46M
Shares Float1.32M
Beta1.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 2 analystsTarget 10.00
  • Strong Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
21.25%
Insiders
0.95%
Retail / Other
77.80%

Top Institutional Holders

  • Stonepine Capital Management Llc
    61.00K4.17%
  • Ikarian Capital, LLC
    45.83K3.14%
  • Geode Capital Management, LLC
    23.19K1.59%
  • BOOTHBAY FUND MANAGEMENT, LLC
    13.52K0.93%
  • Tower Research Capital LLC
    1.31K0.09%
  • UBS Group AG
    7290.05%
  • BARRETT & COMPANY, INC.
    80.00%
  • Mccormack Advisors International
    30.00%
  • Caitong International Asset Management Co., Limited.
    10.00%
  • Citigroup Inc
    10.00%
  • Danske Bank A/S.
    10.00%
  • DRW Securities, LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    8.32K0.57%
  • Fidelity Series Total Market Index
    5550.04%

Stock Splits

  • Jul 22, 20251:12
  • Feb 21, 20251:50
  • Jun 5, 20241:50
  • Nov 29, 20221:30